FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379282929> ?p ?o ?g. }

• W4379282929 endingPage "3115" @default.
• W4379282929 startingPage "3115" @default.
• W4379282929 abstract "3115 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with solid tumors with BRCA1/2 mut treated with Tala are reported. Methods: Eligible pts had measurable disease, ECOG performance status (PS) 0-2, adequate organ function, and no standard treatment (tx) options. Genomic testing was performed in CLIA-certified, CAP-accredited site selected labs. Pts received 1 mg of Tala orally daily until disease progression. Primary endpoint was disease control (DC) per investigator defined as complete (CR) or partial (PR) response or stable disease (SD) of at least 16+ weeks (wks) duration (SD16+) per RECIST v1.1. The hypothesized null DC rate of 15% was evaluated by a 1-sided exact binomial test (alpha 0.10; 82% power). Secondary endpoints were progression-free survival (PFS), overall survival (OS), duration of response (DOR) and SD, and safety. DOR is defined as time from pt’s first documented objective response (OR) to progressive disease (PD). Duration of SD is defined as time from tx start to PD. Results: 28 pts with 16 solid tumors (6/28 pts had lung cancer) with BRCA1 (n=9) , BRCA2 (n=16) , or BRCA1/2 (n=3) mut were enrolled from Dec 2019 to Sept 2021. All pts were included in efficacy analyses. Demographics and outcomes are shown. 1 CR, 9 PR and 6 SD16+ were observed for a DC rate of 57% (1-sided 90% CI: 43% to 100%) and an OR rate of 36% (95% CI: 19% to 56%); the null hypothesis of a 15% DC rate was rejected (p<0.001). 11/16 pts with OR or SD16+ had a BRCA2 mut, 4 had BRCA1 mut, and 1 had both. The pt with a CR (duration of 93 wks) had non-melanoma skin cancer, with BRCA2 and ATM muts, and was microsatellite instability high with 41 muts per megabase. Pts with PR had various solid tumors; 6/9 pts had BRCA2 mut, 2 had BRCA1 mut , 1 had both. Of pts with DC, 11 had tumor types for which PARP inhibitors are not yet FDA approved. Median duration of PR was 20 wks (range, 11-80). 10/16 pts with DC had a co-alteration in the 24 homologous recombination-related genes examined, mainly ATM (3) or ARID1A (2). 13 pts had ≥1 grade 3 tx-related adverse or serious adverse events including: anemia, AST or bilirubin increase, hyponatremia, nausea, vomiting, neutrophil, platelet, or white blood cell decrease. Conclusions: Tala demonstrated antitumor activity in heavily pretreated pts with advanced solid tumors with BRCA1/2 mut. Additional study is warranted to confirm the efficacy of Tala in non-breast, non-ovarian cancer pts with BRCA1/2 mut. Clinical trial information: NCT02693535 . [Table: see text]" @default.
• W4379282929 created "2023-06-05" @default.
• W4379282929 creator A5003341212 @default.
• W4379282929 creator A5004690917 @default.
• W4379282929 creator A5016528073 @default.
• W4379282929 creator A5023651022 @default.
• W4379282929 creator A5024129361 @default.
• W4379282929 creator A5031299191 @default.
• W4379282929 creator A5032230772 @default.
• W4379282929 creator A5038911499 @default.
• W4379282929 creator A5041306590 @default.
• W4379282929 creator A5042358497 @default.
• W4379282929 creator A5047690131 @default.
• W4379282929 creator A5058562764 @default.
• W4379282929 creator A5068387334 @default.
• W4379282929 creator A5070120524 @default.
• W4379282929 creator A5071405384 @default.
• W4379282929 creator A5071424584 @default.
• W4379282929 creator A5078986413 @default.
• W4379282929 creator A5085149228 @default.
• W4379282929 creator A5092083646 @default.
• W4379282929 date "2023-06-01" @default.
• W4379282929 modified "2023-10-14" @default.
• W4379282929 title "Talazoparib (Tala) in patients (pts) with solid tumors with <i>BRCA1/2 </i>mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study." @default.
• W4379282929 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.3115" @default.
• W4379282929 hasPublicationYear "2023" @default.
• W4379282929 type Work @default.
• W4379282929 citedByCount "0" @default.
• W4379282929 crossrefType "journal-article" @default.
• W4379282929 hasAuthorship W4379282929A5003341212 @default.
• W4379282929 hasAuthorship W4379282929A5004690917 @default.
• W4379282929 hasAuthorship W4379282929A5016528073 @default.
• W4379282929 hasAuthorship W4379282929A5023651022 @default.
• W4379282929 hasAuthorship W4379282929A5024129361 @default.
• W4379282929 hasAuthorship W4379282929A5031299191 @default.
• W4379282929 hasAuthorship W4379282929A5032230772 @default.
• W4379282929 hasAuthorship W4379282929A5038911499 @default.
• W4379282929 hasAuthorship W4379282929A5041306590 @default.
• W4379282929 hasAuthorship W4379282929A5042358497 @default.
• W4379282929 hasAuthorship W4379282929A5047690131 @default.
• W4379282929 hasAuthorship W4379282929A5058562764 @default.
• W4379282929 hasAuthorship W4379282929A5068387334 @default.
• W4379282929 hasAuthorship W4379282929A5070120524 @default.
• W4379282929 hasAuthorship W4379282929A5071405384 @default.
• W4379282929 hasAuthorship W4379282929A5071424584 @default.
• W4379282929 hasAuthorship W4379282929A5078986413 @default.
• W4379282929 hasAuthorship W4379282929A5085149228 @default.
• W4379282929 hasAuthorship W4379282929A5092083646 @default.
• W4379282929 hasConcept C126322002 @default.
• W4379282929 hasConcept C143998085 @default.
• W4379282929 hasConcept C203092338 @default.
• W4379282929 hasConcept C207103383 @default.
• W4379282929 hasConcept C2776694085 @default.
• W4379282929 hasConcept C2777063308 @default.
• W4379282929 hasConcept C2778822529 @default.
• W4379282929 hasConcept C2779134260 @default.
• W4379282929 hasConcept C2779984678 @default.
• W4379282929 hasConcept C2780739268 @default.
• W4379282929 hasConcept C3019894029 @default.
• W4379282929 hasConcept C44249647 @default.
• W4379282929 hasConcept C535046627 @default.
• W4379282929 hasConcept C71924100 @default.
• W4379282929 hasConcept C72563966 @default.
• W4379282929 hasConcept C90924648 @default.
• W4379282929 hasConceptScore W4379282929C126322002 @default.
• W4379282929 hasConceptScore W4379282929C143998085 @default.
• W4379282929 hasConceptScore W4379282929C203092338 @default.
• W4379282929 hasConceptScore W4379282929C207103383 @default.
• W4379282929 hasConceptScore W4379282929C2776694085 @default.
• W4379282929 hasConceptScore W4379282929C2777063308 @default.
• W4379282929 hasConceptScore W4379282929C2778822529 @default.
• W4379282929 hasConceptScore W4379282929C2779134260 @default.
• W4379282929 hasConceptScore W4379282929C2779984678 @default.
• W4379282929 hasConceptScore W4379282929C2780739268 @default.
• W4379282929 hasConceptScore W4379282929C3019894029 @default.
• W4379282929 hasConceptScore W4379282929C44249647 @default.
• W4379282929 hasConceptScore W4379282929C535046627 @default.
• W4379282929 hasConceptScore W4379282929C71924100 @default.
• W4379282929 hasConceptScore W4379282929C72563966 @default.
• W4379282929 hasConceptScore W4379282929C90924648 @default.
• W4379282929 hasFunder F4320307765 @default.
• W4379282929 hasIssue "16_suppl" @default.
• W4379282929 hasLocation W43792829291 @default.
• W4379282929 hasOpenAccess W4379282929 @default.
• W4379282929 hasPrimaryLocation W43792829291 @default.
• W4379282929 hasRelatedWork W1608269846 @default.
• W4379282929 hasRelatedWork W2150001502 @default.
• W4379282929 hasRelatedWork W2560701509 @default.
• W4379282929 hasRelatedWork W2649565258 @default.
• W4379282929 hasRelatedWork W2809220925 @default.
• W4379282929 hasRelatedWork W2898395149 @default.
• W4379282929 hasRelatedWork W3004966710 @default.
• W4379282929 hasRelatedWork W3081388035 @default.
• W4379282929 hasRelatedWork W3100080748 @default.
• W4379282929 hasRelatedWork W4224039515 @default.
• W4379282929 hasVolume "41" @default.
• W4379282929 isParatext "false" @default.
• W4379282929 isRetracted "false" @default.

• next